Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Pharmaceuticals
… And Joins With SAFC To Make Conjugates
by Ann M. Thayer
October 6, 2014
| A version of this story appeared in
Volume 92, Issue 40
Sigma-Aldrich’s SAFC custom manufacturing business will collaborate with Baxter’s BioPharma Solutions unit to produce antibody-drug conjugates. SAFC will contribute capability for manufacturing drug linkers and conducting conjugations, while Baxter will provide sterile drug product filling and finishing services. Together, the companies hope to provide customers with end-to-end contract manufacturing in which a bulk drug substance conjugated by SAFC is transferred to Baxter for final steps including filling, regulatory testing, and packaging.
You might also like...
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter